Skip to Content
Søg Menu

EHA 2019: EPO is effective in about 70% of patients with autoimmune hemolytic anemia

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Relateret indhold

EHA 2019: Potentiale as standard of care for patients with relapsed/refractory multiple myeloma

/ Paul Richardson
EHA19Myelomatose Play the Video 3:38

EHA 2019: Promising activity for late-stage patients with relapses/refractory multiple myeloma

/ Paul Richardson
EHA19Myelomatose Play the Video 4:32

EHA 2019: Prognostic significance of SAMHD1 expression in diffuse large b-cell lymphoma

/ Georgios Rassidakis
EHA19Lymfom Play the Video 2:46

EHA 2019: Single-nucleotide polymorphism can aid the prognostics of of patients with idiopathic cytopenia of undetermined significance (ICUS)

/ Stine Ulrik Mikkelsen
EHA19 Play the Video 5:46

EHA 2019: Ixazomib did not have an adverse impact on quality of life in newly diagnosed multiple myeloma

/ Fredrik Schjesvold
EHA19Myelomatose Play the Video 3:16

EHA 2019: New data from the Nordic Myeloma Study Group

/ Henrik Gregersen
EHA19Myelomatose Play the Video 1:37

EHA 2019: Nye behandlinger til agressiv diffust storcellet B-lymfom

/ Troels Hammer
EHA19Lymfom Play the Video 3:38

EHA 2019: EPO in treatment of autoimmune hemolytic anemia

/ Sigbjørn Berentsen
EHA19 Play the Video 4:06

EHA 2019: Highly effective combination for initial therapy for young, fit CLL patients

/ Matthew Davids 
EHA19CLL Play the Video 2:46
Back to top